Comparison of Different Risk Classification Systems in 558 Patients with Gastrointestinal Stromal Tumors after R0-Resection
Open Access
- 27 December 2016
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 7, 504
Abstract
Background: Due to adjuvant treatment concepts for patients with R0-resected gastrointestinal stromal tumors (GIST), a reproducible and reliable risk classification system proved of utmost importance for optimal treatment of patients and prediction of prognosis. The aim of this study was to reevaluate the impact of five widely-applied and well-established GIST risk classification systems (i.e. scores by Fletcher, Miettinen, Huang, Joensuu and TNM classification) on a series of 558 GIST patients with long-term follow-up after R0 resection. Methods: Tumor size, mitotic count and site were used in variable combination to predict high- and low risk patients by the use of the five risk classification models. For survival analyses disease-specific survival, disease-free survival and overall-survival were investigated. Patients with initial metastatic disease or incompletely resectable tumors were excluded. Results: All GIST classification models distinguished well between patients with high-risk and low-risk tumors and none of the five risk systems was superior to predict patient outcome. The models showed significant heterogeneity. There was no significant difference between the different risk-groups regarding overall-survival. Subdivision of GIST patients with very low- and low-risk appeared to be negligible. Conclusions: Currently applied GIST risk classification systems are comparable to predict high- or low-risk patients with initial non-metastatic and completely resected GIST. However, the heterogeneity of the high-risk group and the absence of differences in overall survival indicate the need for more precise tumor- and patient-related criteria for better stratification of GIST and identification of patients who would benefit best from adjuvant tyrosine kinase inhibitor therapy.Keywords
This publication has 57 references indexed in Scilit:
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsThe Lancet Oncology, 2012
- A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European regionBritish Journal of Cancer, 2010
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisThe Lancet Oncology, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Risk stratification of patients diagnosed with gastrointestinal stromal tumorHuman Pathology, 2008
- Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based studyBMC Cancer, 2007
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinaseProceedings of the National Academy of Sciences, 2003
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998